2016 Hematological Malignancies
Phase II trial RT and anti-PD1 in early favorable cHL
Classical HL in clinical stage I/II without risk factors* Age 18 - 75
1 x anti-PD-1 antibody #
6 x anti-PD-1 antibody
20 Gy IS-RT §
5 x anti-PD-1 antibody #
20 Gy IS-RT §
* Risk factors: Large med mass, extranodal lesion, elevated ESR, ≥ 3 nodal areas # x mg/kg every 2 weeks § IS-RT starts on day 5 after the first infusion on the anti-PD-1 antibody
Made with FlippingBook